Emmanouil Kalampokas1, Theodoros Kalampokas2, Christos Damaskos3,4. 1. Department of Gynaecological Oncology, Aberdeen Royal Infirmary, Aberdeen, U.K. 2. Second Department of Obstetrics and Gynecology, Aretaieion Hospital, University of Athens Medical School, Athens, Greece. 3. Second Department of Propedeutic Surgery, Laiko General Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece x_damaskos@yahoo.gr. 4. N.S. Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Abstract
Malignant melanoma of the vagina is a rare, aggressive malignancy of poor prognosis. It principally affects post-menopausal women, with a mean age of 57 years, and the factors that contribute to its appearance are not well known. The first case of primary malignant vaginal melanoma was reported in 1887 and modern literature has noted about 500 cases, globally. Vaginal melanomas constitute 0.3% of all malignant melanomas and fewer than 3% of all vaginal carcinomas. To date there is no clear consensus regarding treatment. An early, accurate diagnosis and prompt investigation is essential in reaching appropriate treatment decisions. We present a clinical case of primary vaginal melanoma and review the literature briefly, presenting the current treatment plans and updates of this rare gynecological malignancy. Considerations, epidemiology, associated risk factors, response to therapy and expected outcome are also discussed. CONCLUSION: Primary malignant vaginal melanoma is a rare but aggressive melanoma that affects women in their 6th and 7th decade of life. The tumor appears as a dark node or spindle but can also be amelanotic. The size of the tumor is indicative of the prognostic factors. Surgery seems to be the only efficient treatment. Postoperative adjuvant therapy might help in preventing recurrence of the tumor. The survival rate is largely dependent on nodal and distant metastasis of the disease after initial tumor resection. There is a dire need to form a proper therapeutic regime to control this disease. Copyright
Malignant melanoma of the vagina is a rare, aggressive malignancy of poor prognosis. It principally affects post-menopausal women, with a mean age of 57 years, and the factors that contribute to its appearance are not well known. The first case of primary malignant vaginal melanoma was reported in 1887 and modern literature has noted about 500 cases, globally. Vaginal melanomas constitute 0.3% of all malignant melanomas and fewer than 3% of all vaginal carcinomas. To date there is no clear consensus regarding treatment. An early, accurate diagnosis and prompt investigation is essential in reaching appropriate treatment decisions. We present a clinical case of primary vaginal melanoma and review the literature briefly, presenting the current treatment plans and updates of this rare gynecological malignancy. Considerations, epidemiology, associated risk factors, response to therapy and expected outcome are also discussed. CONCLUSION: Primary malignant vaginal melanoma is a rare but aggressive melanoma that affects women in their 6th and 7th decade of life. The tumor appears as a dark node or spindle but can also be amelanotic. The size of the tumor is indicative of the prognostic factors. Surgery seems to be the only efficient treatment. Postoperative adjuvant therapy might help in preventing recurrence of the tumor. The survival rate is largely dependent on nodal and distant metastasis of the disease after initial tumor resection. There is a dire need to form a proper therapeutic regime to control this disease. Copyright
Authors: Elizabeth C Smyth; Marisa Flavin; Melissa P Pulitzer; Ginger J Gardner; Peter D Costantino; Dennis S Chi; Kita Bogatch; Paul B Chapman; Jedd D Wolchok; Gary K Schwartz; Richard D Carvajal Journal: J Clin Oncol Date: 2011-10-17 Impact factor: 44.544
Authors: S Samolis; P Panagopoulos; N Kanellopoulos; I Papastefanou; S Karadaglis; M Katsoulis Journal: Eur J Gynaecol Oncol Date: 2010 Impact factor: 0.196
Authors: Susan Seifried; Lauren E Haydu; Michael J Quinn; Richard A Scolyer; Jonathan R Stretch; John F Thompson Journal: Ann Surg Oncol Date: 2014-11-11 Impact factor: 5.344
Authors: Carol Beadling; Erick Jacobson-Dunlop; F Stephen Hodi; Claudia Le; Andrea Warrick; Janice Patterson; Ajia Town; Amy Harlow; Frank Cruz; Sharl Azar; Brian P Rubin; Susan Muller; Rob West; Michael C Heinrich; Christopher L Corless Journal: Clin Cancer Res Date: 2008-11-01 Impact factor: 12.531
Authors: Elena-Codruța Dobrică; Cristina Vâjâitu; Carmen Elena Condrat; Dragoș Crețoiu; Ileana Popa; Bogdan Severus Gaspar; Nicolae Suciu; Sanda Maria Crețoiu; Valentin Nicolae Varlas Journal: Biomedicines Date: 2021-06-30